The Lectenz Bio team is excited to announce the approval of its first patent for a carbohydrate-like small molecule inhibitor.
This expands the Lectenz® product pipeline with a small molecule glycomimetic which has therapeutic potential as a flu inhibitor. This paves the way for more research and development for both Lectenz® and GlycoSense™ products.
More about the patent:
Glycomimetics to Inhibit Pathogen-Host Interactions. U.S. Patent Number 9,605,014. This patent is for carbohydrate-like small molecule inhibitors. (Patent issued by USPTO March 28, 2017.)
